FIELD: biotechnology; veterinary medicine.
SUBSTANCE: vaccine for contribution to prevention of a disease caused by a rabies virus is proposed, containing RNA-replicon alphavirus particle, which encodes a rabies virus antigen, and a pharmaceutically acceptable carrier. A method for immunization of a mammal against a rabies virus is proposed, including administration to the mammal of a single dose of immunologically effective amount of the vaccine.
EFFECT: vaccination with different doses of RP-vaccine against a rabies virus gives higher group geometrical average titers against a rabies virus, according to RFFIT, than vaccination with the present licensed commercial product against rabies, which has an indication on a label on three year duration of the immunity; long-term protection is achieved using a single dose.
14 cl, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT VACCINE FOR CATS | 2018 |
|
RU2797538C2 |
| VACCINE AGAINST FELINE CALICIVIRUS | 2018 |
|
RU2792898C2 |
| VACCINE AGAINST FELINE LEUKEMIA VIRUS | 2018 |
|
RU2784533C2 |
| VACCINE TO SWINE INFLUENZA A VIRUS | 2018 |
|
RU2787596C2 |
| ALPHAVIRUS REPLICON PARTICLE | 2018 |
|
RU2795596C2 |
| RABIES VACCINE | 2014 |
|
RU2712743C2 |
| NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND APPLICATIONS THEREOF | 2018 |
|
RU2816240C2 |
| FMDV-E2 FUSION PROTEINS AND USE THEREOF | 2016 |
|
RU2714428C2 |
| MYCOBACTERIAL ANTIGEN COMPOSITION | 2015 |
|
RU2702194C2 |
| CHIMERIC VACCINES BASED ON VIRUSES OF FLAVIVIRUS AND LYSSAVIRUS GENES | 2019 |
|
RU2816136C2 |
